183 related articles for article (PubMed ID: 22654951)
1. Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation.
Levina V; Su Y; Gorelik E
Clin Dev Immunol; 2012; 2012():173029. PubMed ID: 22654951
[TBL] [Abstract][Full Text] [Related]
2. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
[TBL] [Abstract][Full Text] [Related]
3. miR-448 targets IDO1 and regulates CD8
Lou Q; Liu R; Yang X; Li W; Huang L; Wei L; Tan H; Xiang N; Chan K; Chen J; Liu H
J Immunother Cancer; 2019 Aug; 7(1):210. PubMed ID: 31391111
[TBL] [Abstract][Full Text] [Related]
4. IDO1 impairs NK cell cytotoxicity by decreasing NKG2D/NKG2DLs via promoting miR-18a.
Zhang J; Han X; Hu X; Jin F; Gao Z; Yin L; Qin J; Yin F; Li C; Wang Y
Mol Immunol; 2018 Nov; 103():144-155. PubMed ID: 30268986
[TBL] [Abstract][Full Text] [Related]
5. 4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth.
Panda S; Pradhan N; Chatterjee S; Morla S; Saha A; Roy A; Kumar S; Bhattacharyya A; Manna D
Sci Rep; 2019 Dec; 9(1):18455. PubMed ID: 31804586
[TBL] [Abstract][Full Text] [Related]
6. Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration.
Liu XQ; Lu K; Feng LL; Ding M; Gao JM; Ge XL; Wang X
Leuk Lymphoma; 2014 Feb; 55(2):405-14. PubMed ID: 23682557
[TBL] [Abstract][Full Text] [Related]
7. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
8. Effects of upregulated indoleamine 2, 3-dioxygenase 1 by interferon γ gene transfer on interferon γ-mediated antitumor activity.
Watcharanurak K; Zang L; Nishikawa M; Yoshinaga K; Yamamoto Y; Takahashi Y; Ando M; Saito K; Watanabe Y; Takakura Y
Gene Ther; 2014 Sep; 21(9):794-801. PubMed ID: 24919418
[TBL] [Abstract][Full Text] [Related]
9. IDO is a nodal pathogenic driver of lung cancer and metastasis development.
Smith C; Chang MY; Parker KH; Beury DW; DuHadaway JB; Flick HE; Boulden J; Sutanto-Ward E; Soler AP; Laury-Kleintop LD; Mandik-Nayak L; Metz R; Ostrand-Rosenberg S; Prendergast GC; Muller AJ
Cancer Discov; 2012 Aug; 2(8):722-35. PubMed ID: 22822050
[TBL] [Abstract][Full Text] [Related]
10. Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1.
Werfel TA; Elion DL; Rahman B; Hicks DJ; Sanchez V; Gonzales-Ericsson PI; Nixon MJ; James JL; Balko JM; Scherle PA; Koblish HK; Cook RS
Cancer Res; 2019 Jan; 79(1):171-182. PubMed ID: 30413412
[TBL] [Abstract][Full Text] [Related]
11. Gene silencing of indoleamine 2,3-dioxygenase 2 in melanoma cells induces apoptosis through the suppression of NAD+ and inhibits in vivo tumor growth.
Liu Y; Zhang Y; Zheng X; Zhang X; Wang H; Li Q; Yuan K; Zhou N; Yu Y; Song N; Fu J; Min W
Oncotarget; 2016 May; 7(22):32329-40. PubMed ID: 27058624
[TBL] [Abstract][Full Text] [Related]
12. Tumoral indoleamine 2, 3-dioxygenase 1 is regulated by monocytes and T lymphocytes collaboration in hepatocellular carcinoma.
Zhao Q; Wang PP; Huang ZL; Peng L; Lin C; Gao Z; Su S
Oncotarget; 2016 Mar; 7(12):14781-90. PubMed ID: 26895379
[TBL] [Abstract][Full Text] [Related]
13. Mechanism and prognostic value of indoleamine 2,3-dioxygenase 1 expressed in hepatocellular carcinoma.
Li S; Han X; Lyu N; Xie Q; Deng H; Mu L; Pan T; Huang X; Wang X; Shi Y; Zhao M
Cancer Sci; 2018 Dec; 109(12):3726-3736. PubMed ID: 30264546
[TBL] [Abstract][Full Text] [Related]
14. Gene silencing of indoleamine 2,3-dioxygenase hinders tumor growth through angiogenesis inhibition.
Pan J; Yuan K; Peng S; Huang Y; Zhang Y; Hu Y; Feng Y; Shi Y; Liu Y; Wang H; Zhou N; Min W
Int J Oncol; 2017 Jun; 50(6):2136-2144. PubMed ID: 28498425
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM/CD3-bispecific BiTE antibody MT110 efficacy against IDO1
Hong R; Zhou Y; Tian X; Wang L; Wu X
Int Immunopharmacol; 2018 Jan; 54():118-124. PubMed ID: 29128855
[TBL] [Abstract][Full Text] [Related]
16. Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers.
Noonepalle SK; Gu F; Lee EJ; Choi JH; Han Q; Kim J; Ouzounova M; Shull AY; Pei L; Hsu PY; Kolhe R; Shi F; Choi J; Chiou K; Huang TH; Korkaya H; Deng L; Xin HB; Huang S; Thangaraju M; Sreekumar A; Ambs S; Tang SC; Munn DH; Shi H
Cancer Immunol Res; 2017 Apr; 5(4):330-344. PubMed ID: 28264810
[TBL] [Abstract][Full Text] [Related]
17. Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance.
Hennequart M; Pilotte L; Cane S; Hoffmann D; Stroobant V; Plaen E; Van den Eynde BJ
Cancer Immunol Res; 2017 Aug; 5(8):695-709. PubMed ID: 28765120
[TBL] [Abstract][Full Text] [Related]
18. Forced IDO1 expression in dendritic cells restores immunoregulatory signalling in autoimmune diabetes.
Pallotta MT; Orabona C; Bianchi R; Vacca C; Fallarino F; Belladonna ML; Volpi C; Mondanelli G; Gargaro M; Allegrucci M; Talesa VN; Puccetti P; Grohmann U
J Cell Mol Med; 2014 Oct; 18(10):2082-91. PubMed ID: 25215657
[TBL] [Abstract][Full Text] [Related]
19. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells.
Opitz CA; Litzenburger UM; Opitz U; Sahm F; Ochs K; Lutz C; Wick W; Platten M
PLoS One; 2011; 6(5):e19823. PubMed ID: 21625531
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
